Mylan Commemorates 24th World AIDS Day

                    Mylan Commemorates 24th World AIDS Day

PR Newswire

PITTSBURGH, Dec. 1, 2012

PITTSBURGH, Dec. 1, 2012 /PRNewswire/ --Mylan Inc. (Nasdaq: MYL) today joins
communities around the world to commemorate the 24th World AIDS Day by
honoring those who have battled HIV/AIDS, celebrating the progress achieved to
date in the global response to the disease, and reaffirming Mylan's passionate
commitment to the ongoing fight against HIV/AIDS.

Mylan CEO Heather Bresch said, "Mylan is dedicated to expanding access to high
quality antiretroviral medications (ARVs) for those in need. On this 24th
World AIDS Day, we stand ready to continue contributing to the fight against
HIV/AIDS in 2013 and beyond, and believe that an AIDS-free generation is
within our grasp."

Mylan continues to support the pledge the U.S. government made on World AIDS
Day 2011 to provide treatment to 6 million people through the U.S. President's
Emergency Plan for AIDS Relief (PEPFAR) by the end of 2013. PEPFAR was
established in 2003 to help save those suffering from HIV/AIDS around the
world. To date, the program has helped 4.5 million people in resource-limited
areas receive treatment.

Mylan also continues to support the United Nations' "15 by 15" goal. If met,
by 2015 the 15 million people who, according to the World Health
Organization's (WHO) 2010 ARV Treatment Guidelines, need antiretroviral
therapy would be receiving it.

In order to increase and expand access to ARV medications used to treat
HIV/AIDS, Mylan believes it is imperative to focus on enhancing mobility and
supply-chain management. As a company with a proven track record for exemplary
supply-chain management, Mylan is confident its insights can help shape the
global community's efforts to improve access to this vital medicine.

Bresch continued, "We are doing all we can to expand access to life-saving
ARVs by scaling up to meet unmet needs and breaking down barriers that stand
in the way of getting medicine to people who need it. For the last decade,
Mylan has focused on driving down the costs of ARV medicines. Today, the
primary barrier standing between patients and treatment is not the cost of
drugs, but inadequate access to them. Our aim is to do for access what we
already have done for affordability."

In addition to helping enhance affordability of ARV drugs, the company also
has helped increase access to these medications by introducing a number of ARV
innovations, for instance producing single blister "combo" packs, which
provide a reduced pill burden and once-a-day dosage. Mylan also developed
three FDA/WHO-approved heat-stable ARV products, which can be distributed and
used in warm climates where refrigeration infrastructure is not widely
available. In addition, Mylan has been a global leader in producing ARV
formulations for pediatric use.

According to WHO, HIV is one of the world's leading infectious killers,
claiming more than 25 million lives over the last 30 years. In 2011, there
were approximately 34.2 million people living with HIV. Today, approximately
one-third of all people in the developing world receiving treatment for
HIV/AIDS are taking a Mylan product.

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit, do what's right, not what's easy
and impact the future through passionate global leadership. We offer a growing
portfolio of more than 1,100 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which approximately one-third of HIV/AIDS patients in developing
countries depend. We also operate one of the largest active pharmaceutical
ingredient manufacturers and currently market products in approximately 150
countries and territories. Our workforce of more than 18,000 people is
dedicated to improving the customer experience and increasing pharmaceutical
access to consumers around the world. But don't take our word for it. See for
yourself. See inside.

SOURCE Mylan Inc.

Contact: Nina Devlin (Media), +1-724-514-1968, Kris King (Investors),
Press spacebar to pause and continue. Press esc to stop.